Article Data

  • Views 940
  • Dowloads 178

Original Research

Open Access

FloSeal for preventing symptomatic lymphocele after pelvic and/or para-aortic lymphadenectomy in gynecological cancers: a randomized controlled trial

  • Jeong-Yeol Park1,*,
  • Min-Hyun Baek2
  • Joo-Hyun Nam1

1Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 05505 Seoul, Republic of Korea

2Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, 10408 Goyang-si, Republic of Korea

DOI: 10.22514/ejgo.2023.080 Vol.44,Issue 5,October 2023 pp.67-74

Submitted: 08 April 2023 Accepted: 24 May 2023

Published: 15 October 2023

*Corresponding Author(s): Jeong-Yeol Park E-mail:;


To evaluate the role of FloSeal for preventing symptomatic lymphocele following pelvic and/or para-aortic lymphadenectomy in patients with gynecological cancers. Between October 2014 and April 2015, 40 patients with gynecological cancers planned for surgical management were randomly placed into FloSeal and non-FloSeal groups in a 1:1 ratio. Lymphocele incidence was evaluated using intravenous contrast-enhanced, abdominopelvic computed tomography 3–6 months after surgery. The quality of life questionnaire was completed by patients at 1, 3 and 6 months after surgery. The incidence of symptomatic lymphocele was compared using a chi-square test. All patients underwent bilateral pelvic lymph node dissection, and eight patients in each group (40%vs. 44.4%, p > 0.999) underwent para-aortic lymph node dissection. The mean number of total, right pelvic, left pelvic and para-aortic lymph nodes retrieved was similar between the groups. One patient (1/20, 5%) in the FloSeal group and three (3/18, 16.7%) in the non-FloSeal group developed lymphoceles (p = 0.328). The incidence of symptomatic lymphocele was 0% and 11% (2/18) in the FloSeal and non-FloSeal groups (p = 0.218), respectively. The mean time interval to drain removal (4.8 ± 2.0 days vs. 5.3 ± 2.2 days, p = 0.400) was shorter and the mean drain volume (1656 ± 1362 mL vs. 2022 ± 2301 mL, p = 0.550) was smaller in FloSeal group. The use of FloSeal after pelvic and/or para-aortic lymphadenectomy in patients with gynecological cancers may be effective for preventing symptomatic lymphocele. Clinical Trial registration: NCT01679483.


Lymphocele; Lymphocyst; Lymphadenectomy; Lymph node dissection; Gynecological cancer; FloSeal

Cite and Share

Jeong-Yeol Park,Min-Hyun Baek,Joo-Hyun Nam. FloSeal for preventing symptomatic lymphocele after pelvic and/or para-aortic lymphadenectomy in gynecological cancers: a randomized controlled trial. European Journal of Gynaecological Oncology. 2023. 44(5);67-74.


[1] Tzanis AA, Antoniou SA, Zacharoulis D, Ntafopoulos K, Tsouvali H, Daponte A. The role of systematic pelvic and para-aortic lymphadenectomy in the management of patients with advanced epithelial ovarian, tubal, and peritoneal cancer: a systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2023; 285: 198–203.

[2] Song SY, Park M, Kang BH, Yang JB, Ko YB, Lee M, et al. Distribution of lymphocele following lymphadenectomy in patients with gynecological malignancies. Obstetrics & Gynecology Science. 2020; 63: 700–708.

[3] Volpi L, Sozzi G, Capozzi VA, Ricco’ M, Merisio C, Di Serio M, et al. Long term complications following pelvic and para-aortic lymphadenectomy for endometrial cancer, incidence and potential risk factors: a single institution experience. International Journal of Gynecologic Cancer. 2019; 29: 312–319.

[4] Charoenkwan K, Kietpeerakool C. Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies. Cochrane Database of Systematic Reviews. 2017; 6: CD007387.

[5] Ma X, Wang Y, Fan A, Dong M, Zhao X, Zhang X, et al. Risk factors, microbiology and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies. Archives of Gynecology and Obstetrics. 2018; 298: 1195–1203.

[6] Tinelli A, Giorda G, Manca C, Pellegrino M, Prudenzano R, Guido M, et al. Prevention of lymphocele in female pelvic lymphadenectomy by a collagen patch coated with the human coagulation factors: a pilot study. Journal of Surgical Oncology. 2012; 105: 835–840.

[7] Zikan M, Fischerova D, Pinkavova I, Slama J, Weinberger V, Dusek L, et al. A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. Gynecologic Oncology. 2015; 137: 291–298.

[8] Aznar AL, Lloret PE, Moreno CS, Luna-Guibourg R, Negre RR. Laparoscopic approach for symptomatic pelvic and para-aortic lymphoceles. Journal of the Turkish-German Gynecological Association. 2022; 23: 60–62.

[9] Ayhan A, Basaran A, Güler TO. Effects of oxidized regenerated methylcellulose on lymphocyst formation and peritoneum in gynecologic cancer patients. International Journal of Gynecological Cancer. 2010; 20: 23–27.

[10] Sahbaz A, Gungorduk K, Gulseren V, Ozdemir IA, Harma M, Harma M, et al. What are the risk factors for lymphocyst formation apart from lymphnode dissection and lymphnode count in gynecologic malignancy? Geburtshilfe Frauenheilkd. 2016; 76: 403–407.

[11] Prodromidou A, Iavazzo C, Fotiou A, Psomiadou V, Drakou M, Vorgias G, et al. The application of fibrin sealant for the prevention of lymphocele after lymphadenectomy in patients with gynecological malignancies: a systematic review and meta-analysis of randomized controlled trials. Gynecologic Oncology. 2019; 153: 201–208.

[12] Wagner J, McLaughlin T, Pinto K, Tortora J, Gangakhedkar A, Staff I. The effect of a peritoneal iliac flap on lymphocele formation after robotic radical prostatectomy: results from the PLUS trial. Urology. 2023; 173: 104–110.

[13] Waldert M, Remzi M, Klatte T, Klingler HC. Floseal reduces the incidence of lymphoceles after lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy. Journal of Endourology. 2011; 25: 969–973.

[14] Park J, Nam J. Role of robotic surgery in cervical malignancy. Best Practice & Research Clinical Obstetrics & Gynaecology. 2017; 45: 60–73.

[15] Kakubari R, Kobayashi E, Kakuda M, Iwamiya T, Takiuchi T, Kodama M, et al. Postoperative lymphocyst formation after pelvic lymphadenectomy for gynecologic cancers: comparison between laparoscopy and laparotomy. International Journal of Clinical Oncology. 2022; 27: 602–608.

[16] Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Systematic Reviews. 2017; 10: CD007585.

[17] Park NY, Seong WJ, Chong GO, Hong DG, Cho YL, Park IS, et al. The effect of nonperitonization and laparoscopic lymphadenectomy for minimizing the incidence of lymphocyst formation after radical hysterectomy for cervical cancer. International Journal of Gynecological Cancer. 2010; 20: 443–448.

[18] Matthey-Gié M, Gié O, Deretti S, Demartines N, Matter M. Prospective randomized study to compare lymphocele and lymphorrhea control following inguinal and axillary therapeutic lymph node dissection with or without the use of an ultrasonic scalpel. Annals of Surgical Oncology. 2016; 23: 1716–1720.

[19] Lamblin G, Chauvy L, Rannou C, Mathevet P, Chabert P, Mellier G, et al. Does ultrasonic advanced energy reduce lymphocele incidence in laparoscopic para-aortic lymphadenectomy? European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015; 185: 53–58.

[20] Scholz HS, Petru E, Benedicic C, Haas J, Tamussino K, Winter R. Fibrin application for preventing lymphocysts after retroperitoneal lymphadenectomy in patients with gynecologic malignancies. Gynecologic Oncology. 2002; 84: 43–46.

[21] Grimm C, Polterauer S, Helmy S, Zikan M, Cibula D, Heitz F, et al. A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial. BMC Cancer. 2014; 14: 635.

[22] Köhler C, Kyeyamwa S, Marnitz S, Tsunoda A, Vercelino F, Schneider A, et al. Prevention of lymphoceles using floseal and coseal after laparoscopic lymphadenectomy in patients with gynecologic malignancies. Journal of Minimally Invasive Gynecology. 2015; 22: 451–455.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time